A 3D Tissue Model of Traumatic Brain Injury with Excitotoxicity That Is Inhibited by Chronic Exposure to Gabapentinoids.
3D neural tissues
excitotoxicity
tissue engineering
traumatic brain injury
voltage-gated calcium channels
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
17 08 2020
17 08 2020
Historique:
received:
11
06
2020
revised:
10
08
2020
accepted:
12
08
2020
entrez:
23
8
2020
pubmed:
23
8
2020
medline:
16
6
2021
Statut:
epublish
Résumé
Injury progression associated with cerebral laceration is insidious. Following the initial trauma, brain tissues become hyperexcitable, begetting further damage that compounds the initial impact over time. Clinicians have adopted several strategies to mitigate the effects of secondary brain injury; however, higher throughput screening tools with modular flexibility are needed to expedite mechanistic studies and drug discovery that will contribute to the enhanced protection, repair, and even the regeneration of neural tissues. Here we present a novel bioengineered cortical brain model of traumatic brain injury (TBI) that displays characteristics of primary and secondary injury, including an outwardly radiating cell death phenotype and increased glutamate release with excitotoxic features. DNA content and tissue function were normalized by high-concentration, chronic administrations of gabapentinoids. Additional experiments suggested that the treatment effects were likely neuroprotective rather than regenerative, as evidenced by the drug-mediated decreases in cell excitability and an absence of drug-induced proliferation. We conclude that the present model of traumatic brain injury demonstrates validity and can serve as a customizable experimental platform to assess the individual contribution of cell types on TBI progression, as well as to screen anti-excitotoxic and pro-regenerative compounds.
Identifiants
pubmed: 32824600
pii: biom10081196
doi: 10.3390/biom10081196
pmc: PMC7463727
pii:
doi:
Substances chimiques
Glutamic Acid
3KX376GY7L
Gabapentin
6CW7F3G59X
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Paul G. Allen Family Foundation
ID : 12171
Pays : International
Organisme : NINDS NIH HHS
ID : R01 NS092847
Pays : United States
Organisme : NIMH NIH HHS
ID : F32 MH118678
Pays : United States
Organisme : NIH HHS
ID : S10 OD021624
Pays : United States
Références
Handb Clin Neurol. 2015;127:45-66
pubmed: 25702209
Pharmaceuticals (Basel). 2013 Jun 26;6(7):788-812
pubmed: 24276315
Brain Res Bull. 1998 Jul 1;46(4):281-309
pubmed: 9671259
Stem Cell Reports. 2016 Sep 13;7(3):557-570
pubmed: 27569063
J Neurochem. 1993 Dec;61(6):2015-24
pubmed: 7504079
J Neurosci Methods. 2012 Jul 30;209(1):199-211
pubmed: 22698665
J Neurotrauma. 2012 Apr 10;29(6):1054-70
pubmed: 22017610
Stroke. 2009 Aug;40(8):e519-22
pubmed: 19520992
Biochim Biophys Acta. 2007 Apr;1772(4):457-66
pubmed: 17158035
Prog Polym Sci. 2007;32(8-9):991-1007
pubmed: 19543442
Br J Anaesth. 2007 Jul;99(1):4-9
pubmed: 17573392
Neurology. 2002 Nov 12;59(9 Suppl 5):S21-6
pubmed: 12428028
Neurosci Lett. 2008 Dec 12;447(2-3):120-3
pubmed: 18723075
PLoS One. 2011;6(9):e24341
pubmed: 21957448
Curr Opin Pharmacol. 2006 Feb;6(1):108-13
pubmed: 16376147
J Trauma. 2011 Jun;70(6):1471-9
pubmed: 21817985
CMAJ. 2008 Apr 22;178(9):1163-70
pubmed: 18427091
Biomaterials. 2019 Feb;192:510-522
pubmed: 30529870
Brain Pathol. 2005 Jul;15(3):234-40
pubmed: 16196390
Nat Protoc. 2011 Sep 22;6(10):1612-31
pubmed: 21959241
J Comp Neurol. 1997 Jul 28;384(2):312-20
pubmed: 9215725
Neurosci Lett. 2013 Feb 22;535:90-4
pubmed: 23274708
Epilepsy Res. 2007 Feb;73(2):137-50
pubmed: 17126531
Exp Neurol. 2004 Nov;190(1):70-8
pubmed: 15473981
Acta Neuropathol. 2002 Jun;103(6):607-14
pubmed: 12012093
Cell Death Dis. 2019 Jun 24;10(7):496
pubmed: 31235685
Neuroimage. 2009 Jan 1;44(1):1-8
pubmed: 18804539
Pharmacology. 2002 Aug;65(4):198-203
pubmed: 12119449
Ann Neurol. 2015 Apr;77(4):571-81
pubmed: 25623048
Proc Natl Acad Sci U S A. 2014 Sep 23;111(38):13811-6
pubmed: 25114234
Annu Rev Biomed Eng. 2011 Aug 15;13:91-126
pubmed: 21529164
Acta Neuropathol. 2005 Jun;109(6):603-16
pubmed: 15877231
Neurosci Lett. 1993 Jul 23;157(2):211-4
pubmed: 8233056
J Comp Neurol. 1997 Feb 3;378(1):70-87
pubmed: 9120055
Eur J Anaesthesiol. 1996 May;13(3):247-68
pubmed: 8737117
Epilepsia. 2003 Feb;44(2):150-6
pubmed: 12558567
J Med Chem. 1991 Jul;34(7):2295-8
pubmed: 2067001
J Neurosurg. 1998 Dec;89(6):971-82
pubmed: 9833824
Exp Neurol. 2015 May;267:243-53
pubmed: 25819105
Macromol Biosci. 2020 Mar;20(3):e2000004
pubmed: 32065736
Brain Pathol. 1995 Oct;5(4):397-406
pubmed: 8974622
Eur J Neurosci. 2006 Dec;24(11):3008-16
pubmed: 17156362
Neurochem Int. 2006 Apr;48(5):394-403
pubmed: 16473439
Brain Res. 1994 Jan 7;633(1-2):236-42
pubmed: 7907934
Electroencephalogr Clin Neurophysiol. 1987 Apr;66(4):440-7
pubmed: 2435524
J Trauma Acute Care Surg. 2012 Sep;73(3):654-60
pubmed: 22710775
Neurobiol Dis. 2006 Nov;24(2):357-66
pubmed: 16959492
Biomacromolecules. 2004 May-Jun;5(3):718-26
pubmed: 15132652
Neurosci Lett. 2011 Apr 20;494(1):19-23
pubmed: 21352896
Neurotherapeutics. 2014 Apr;11(2):286-96
pubmed: 24554454
Neuron. 2015 Apr 8;86(1):106-39
pubmed: 25856490
Nat Protoc. 2015 Sep;10(9):1362-73
pubmed: 26270395